An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Cancer Research

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1158/1078-0432.ccr-12-1558